Johnson & Johnson (JNJ)

Morgan Stanley, Pentair, Johnson & Johnson expected to release earnings, ASML posts strong results, Progressive to report

Johnson & Johnson stock trades near all-time highs. A strong Q2 report and the chart show more upside ahead.

Earnings report for JNJ expected on July 15, with analysts predicting $2.85/share & $25.06B revenue. Stock price target raised to $287/share.

The dividend looks secure. The share price is the harder call.

Why are chip stocks collapsing while the Dow barely budges? Korean markets just had their worst day since the 2008 financial crisis, and the fallout is hitting semiconductors hard.

As investors flee this year's high flyers, a few dependable payers are catching the money.

Griffin is at the helm of the world's most profitable hedge fund.

VYM and SCHD both offer low-cost dividend exposure, but differ in methodology, yield, and holdings—VYM emphasizes broad, higher-yield diversification, while SCHD focuses on stricter, dividend-growth criteria.

There are good reasons to invest in Lilly and to hold off.

It's something very simple.

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Kimberly-Clark is far from flashy, but what it lacks in glitz and glam, it makes up for with predictability.

These stocks have long histories of growing their payouts to shareholders.

They may not remain cheap for too much longer.

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.